Methods for treating headache

• US 8,889,151 B2
• Filed: 03/19/2010
• Issued: 11/18/2014
• Est. Priority Date: 02/26/2004
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Turkel, Catherine C., Brin, Mitchell F.
• Primary Examiner(s): Minnifield, Nita M
• Application Number:
  US12/727,960
• Publication Number:
  US 20100189655A1
• Time in Patent Office: 1,705 Days
• US Class Current: 424/247.1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12Y 304/24069 Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Abstract

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.

Claims

1. A method for treating a headache patient with an enhanced therapeutic response to a botulinum toxin treatment of a headache, the method comprising;

identifying and selecting a patient who is not using a prophylactic headache pain medication, wherein the enhanced response is relative to a patient who is using a prophylactic headache pain medication; and

locally administering from between about 105 and about 260 units of botulinum toxin to the patient;

wherein the patient who is not using a prophylactic pain medication and who is being treated with botulinum toxin for a headache experiences at least 0.5 headache-free days (out of a 30-day-month) more than the patient who uses a prophylactic pain medication and who is being treated with botulinum toxin for a headache.

2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.

3. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

4. The method of claim 1, wherein the local administration is by intramuscular or subcutaneous administration to a location on or within the head of a patient.

5. The method of claim 1, wherein the local administration of the botulinum toxin is to a facial muscle of the patient.

6. The method of claim 1, wherein the local administration is to a forehead of the patient.

7. The method of claim 1, wherein the local administration of the botulinum toxin is to a subdermal location or to a muscle location from which the patient perceives a pain to arise.

8. A method for treating a headache patient with an enhanced therapeutic response to a botulinum toxin treatment of a headache, the method comprising identifying and selecting a patient who overuses an acute pain medication, the enhanced response is relative to a patient who is not overusing an acute pain medication;

and locally administering from between about 105 and about 260 units of botulinum toxin to the patient, wherein the patient who overuses an acute pain medication and who is being treated with botulinum toxin for a headache experiences at least 0.7 headache-free days (out of a 30-day-month) more than the patient who does not overuse an acute pain medication and who is being treated with botulinum toxin for a headache.

9. The method of claim 8, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C1, D, E, F and G.

10. The method of claim 8, wherein the botulinum toxin is a botulinum toxin type A.

11. The method of claim 8, wherein the local administration is by intramuscular or subcutaneous administration to a location on or within a head of a patient.

12. The method of claim 8, wherein the local administration of the botulinum toxin is to a facial muscle of the patient.

13. The method of claim 8, wherein the local administration is to a forehead of the patient.

14. The method of claim 8, wherein the local administration of the botulinum toxin is to a subdermal location or to a muscle location from which the patient perceives a pain to arise.